Introduction {#s1}
============

Endometrial carcinoma is a common epithelial malignancy of the endometrium in the female reproductive system worldwide. Its incidence rate is increasing while the age of onset is decreasing each year ([@B1]). The prognosis of endometrial carcinoma depends mainly on the stage of the disease and histological type. The 5-year survival rates of stages I and II endometrial carcinoma are about 80--90 and 70--80%, respectively, while that of stage III and IV disease is 20--60% ([@B2], [@B3]). Some previous studies used biomarkers to estimate the prognosis of endometrial carcinoma. A model used a combination of 7-LncRNA and clinical indicators to predict the survival prognosis of endometrial carcinoma with a C-index of 0.801. Four indicators, including clinical stage, age, pathological grade, and LncRNA were included in the nomogram of prediction; however, the sample size was small ([@B4]). At the same time, there is no accurate estimation of the survival rate of patients with endometrial carcinoma brought about by advancement in medical technology. The evaluation of the improvement of the survival rate due to medical technology among patients with endometrial carcinoma is a subject worthy of further study. The present study has the characteristics of small sample size, insufficient analysis factors, and insufficient data.

The linked Surveillance, Epidemiology, and End Results (SEER) database is a large population-based source of information for all cancer-related epidemiologic and health-related services research. It captures data regarding nearly 25% of the US population, and contains all kinds of clinical information, social information, and cost of treatment, all of which freely provide researchers with enough information ([@B5]). In this study, we assessed endometrial carcinoma patients registered between 1988 and 2015 in the SEER database, and aimed to develop validated prognostic nomograms regarding overall survival (OS) and cancer-specific survival (CSS) to estimate the change in the extent of surveillance from the medical technological progress for endometrial carcinoma patients.

Materials and Methods {#s2}
=====================

Patient Enrollment and Variables
--------------------------------

All patients\' information was obtained from the SEER database using the SEER^\*^Stat software (version 8.3.5; National Cancer Institute, USA).

The time limit for data collection was from 1988 to 2015. The inclusion criteria were as follows: (1) diagnosis of endometrial carcinoma (International Classification of Diseases for Oncology: 8380/3, histology: 8140-8389) and (2) known cause of death and survival duration after diagnosis.

The exclusion criteria were as follows: (1) unknown use of radiotherapy or chemotherapy, (2) unknown diagnostic method, (3) unknown histology grade classification, (4) unknown clinical stage, (5) unknown exact tumor size, (6) unknown metastasis information, and (7) unknown race information of patient.

Data regarding clinical characteristics including age, race, histologic grade, clinical stage, year of diagnosis, tumor size, metastatic status, tissue region, radiation, chemotherapy, survival time, cause of death, and survival status were collected from the SEER database. One lakh thirty nine thousand four hundred and four patients were collected from the SEER database, the data process flowchart was presented in [Figure 1](#F1){ref-type="fig"}. X-tile software (Yale University, New Haven, Connecticut, USA) was used to assess the optimal cut-off values for age, tumor size, and year of diagnosis ([Figure 2](#F2){ref-type="fig"}). The optimal cut-off values for age were 54-, 61-, and 69-years; the optimal cut-off values for tumor size were 29 and 57 mm; the optimal cut-off values for the year of diagnosis were 2001 and 2006. We also used X-tile software to assess the best cut-off for year of diagnosis according to different clinical stages ([Figure 3](#F3){ref-type="fig"}), described as localized, regional, and distant in accordance with the American Joint Committee on Cancer criteria. Radiation status was classified as with radiation and without radiation. Chemotherapy status was classified as with chemotherapy and without chemotherapy.

![The flow chart of data process.](fonc-10-00269-g0001){#F1}

![Identification of optimal cut-off values of age **(A,B)**, tumor size **(C,D)**, and year of diagnosis **(E,F)** via X-tile software analysis. Optimal cut-off values of age were identified as 54, 61 and 69-years based on overall survival. Optimal cut-off values of tumor size were identified as 29 mm and 57 mm based on overall survival. Optimal cut-off values of year of diagnosis were identified as 2001 and 2006 based on overall survival.](fonc-10-00269-g0002){#F2}

![Identification of optimal cut-off values of year of diagnosis \[Stage I **(A,B)**, Stage II **(C,D)**, Stage III **(E,F)**, Stage IV **(G,H)**\]. Optimal cut-off values of year of diagnosis in stage I were identified as 2001 and 2006 based on overall survival. Optimal cut-off values of year of diagnosis in stage II were identified as 2004 and 2009 based on overall survival. Optimal cut-off values of year of diagnosis in stage III were identified as 2001 and 2006 based on overall survival. Optimal cut-off values of year of diagnosis in stage IV were identified as 2002 and 2010 based on overall survival.](fonc-10-00269-g0003){#F3}

According to the inclusion and exclusion criteria, 63,729 patients with endometrial carcinoma were finally enrolled in our study, all of whom were randomly divided into the training cohort (*n* = 42,486) and test cohort (*n* = 21,243) in the ratio 7:3.

The endpoints of our study included CSS and OS; however, the 3- and 5-year survival of both endpoints were used as well.

Statistical Analysis
--------------------

Continuous and categorical data are expressed as frequencies with percentages. A chi-square test was performed to explore the relationship between the clinical features of the two groups. The optimal cut-off values of age, tumor size, and year of diagnosis were assessed using the X-tile software as previously mentioned ([Figure 2](#F2){ref-type="fig"}). Analysis items with *P* \< 0.05 were considered statistically significant. Univariate and multiple Cox regression analysis was used to assess independent survival-related factors among our clinical data. The chi-square test and Cox regression analysis were performed using SPSS version 22.0 (IBM Corp., Armonk, NY, USA). Meanwhile, 95% confidence intervals (CIs) and hazard ratios were calculated. The nomograms according to both cohorts were validated both internally and externally. The C-index (Harrell\'s concordance index) was used to assess the exact prognostic values of nomograms. The verification curve in this study could show the consistency between the actual and predicted nomograms. Nomograms and the verification curve were constructed and adjusted using R version 1.1.453 (The R Development Core Team, Vienna, Austria) in the RStudio environment.

Results {#s3}
=======

Patients\' Basic Information
----------------------------

A total of 63,729 out of 139,404 patients registered with endometrial carcinoma between 1988 and 2015 were enrolled from the SEER database according to the inclusion and exclusion criteria. The patients were divided into the training group (*n* = 42,486) and test group (*n* = 21,243). The basic information of the patients is listed in [Table 1](#T1){ref-type="table"}. There were 53,583 (84.1%) White people, 4,006 (6.3%) black people, and 6,140 (9.6%) people of other races (American Indians/Alaska Natives, and Asian/Pacific Islanders). In all 7,654 (12.0%) people were diagnosed before 2002, 13,809 (21.7%) people were diagnosed between 2002 and 2006, and 42,266 (66.3%) people were diagnosed after 2007. The numbers of people with histologic grades G1, G2, G3, and Gx were 29,028 (45.5%), 22,722 (35.7%), 10,577 (16.6%), and 1,422 (2.2%), respectively. The numbers of people with clinical stages I, II, III, and IV were 47,055 (73.8%), 5,877 (9.2%), 8,212 (12.9%), and 2,585 (4.1%); those with metastatic status M0 and M1 were, respectively, 61,376 (96.3%) and 1,577 (3.7%); and those with localized, regional, and distant surgical stage were, respectively, 46,685 (73.3%), 11,878 (18.6%), and 5,166 (8.1%). The number of patients with and without radiation were, respectively, 48,333 (75.8%) and 15,396 (24.2%); the number of those with and without chemotherapy were, respectively, 53,571 (84.1%) and 10,158 (15.9%); and those with tumor diameter ≤ 28, 29--56, and ≥57 mm were, respectively, 23,219 (36.4%), 26,229 (41.2%), and 14,281(22.4%). The number of patients aged ≤ 54-, 55--61-, 62--69-, and ≥70-years were 17,620 (27.6%), 15,648 (24.6%), 15,001 (23.5%), and 15,460 (24.3%) ([Table 1](#T1){ref-type="table"}). The chi-test for all of those variables between the two groups yielded *P* \> 0.05. In the univariate Cox regression analysis for CSS, except for age between 55- and 61-years, other variables were significantly meaningful (*P* \< 0.05). In the univariate Cox regression for OS, all variables were significant meaningful (*P* \< 0.05) ([Table 2](#T2){ref-type="table"}). In the multivariate Cox regression for CSS, except for "other" in race, and regional in surgical stage, all of other variables were meaningful (*P* \< 0.05). In the multivariate Cox regression for OS, except for regional and distant in surgical stages, all other variables were meaningful (*P* \< 0.05) ([Table 3](#T3){ref-type="table"}).

###### 

Baseline demographic and clinical characteristics of patients with endometrial carcinoma.

  **Variables**                        **Training Cohort (%)**            **Test Cohort (%)**            **Total (%)**   ***P***
  --------------------------- -------- ------------------------- -------- --------------------- -------- --------------- ---------
  Race, *n*, %                                                                                                           0.718
  White                       35,750   84.1                      17,833   83.9                  53,583   84.1            
  Black                       2,648    6.2                       1,358    6.4                   4,006    6.3             
  Other                       4,088    9.6                       2,052    9.7                   6,140    9.6             
  Year of Diagnosis, *n*, %                                                                                              0.713
  ≤ 2001                      5,131    12.1                      2,523    11.9                  7,654    12.0            
  2002--2006                  9,181    21.6                      4,628    21.8                  13,809   21.7            
  ≥2007                       28,174   66.3                      14,092   66.3                  42,266   66.3            
  Histology, *n*, %                                                                                                      0.741
  G1                          19,353   45.6                      9,675    45.5                  29,028   45.5            
  G2                          15,125   35.6                      7,597    35.8                  22,722   35.7            
  G3                          7,041    16.6                      3,516    16.6                  10,577   16.6            
  Gx                          967      2.3                       455      2.1                   1,422    2.2             
  Clinical Stage, *n*, %                                                                                                 0.450
  Stage I                     31,364   73.8                      15,691   73.9                  47,055   73.8            
  Stage II                    3,873    9.1                       2,004    9.4                   5,877    9.2             
  Stage III                   5,512    13.0                      2700     12.7                  8,212    12.9            
  Stage IV                    1,737    4.1                       848      4.0                   2,585    4.1             
  Metastasis, *n*, %                                                                                                     0.710
  M0                          40,909   96.3                      20,467   96.3                  61,376   96.3            
  M1                          1,577    3.7                       776      3.7                   2,353    3.7             
  Surgical Stage, *n*, %                                                                                                 0.128
  Localized                   31,110   73.2                      15,575   73.3                  46,685   73.3            
  Regional                    7,871    18.5                      4,007    18.9                  11,878   18.6            
  Distant                     3,505    8.2                       1,661    7.8                   5,166    8.1             
  Radiation, *n*, %                                                                                                      0.120
  NO                          32,300   76.0                      16,033   75.5                  48,333   75.8            
  YES                         10,186   24.0                      5,210    24.5                  15,396   24.2            
  Chemotherapy, *n*, %                                                                                                   0.233
  NO                          35,662   83.9                      17,909   84.3                  53,571   84.1            
  YES                         6,824    16.1                      3,334    15.7                  10,158   15.9            
  Tumor Size, *n*, %                                                                                                     0.854
  ≤ 28                        15,510   36.5                      7,709    36.3                  23,219   36.4            
  29--56                      17,474   41.1                      8,755    41.2                  26,229   41.2            
  ≥57                         9,502    22.4                      4,779    22.5                  14,281   22.4            
  Age, *n*, %                                                                                                            0.293
  ≤ 54                        11,699   27.5                      5,921    27.9                  17,620   27.6            
  55--61                      10,420   24.5                      5,228    24.6                  15,648   24.6            
  62--69                      9,964    23.5                      5,037    23.7                  15,001   23.5            
  ≥70                         10,403   24.5                      5,057    23.8                  15,460   24.3            

*Gx means undifferentiated tissue cells*.

###### 

Univariate cox regression analysis of cancer-specific survival and Overall survival in the training cohort.

  **Variables**                           **Cancer-specific survival**                                                              **Overall survival**   
  ----------------------- --------------- ------------------------------ ------------------------------------------ --------------- ---------------------- ------------------------------------------
  **AGE**                                                                                                                                                  
  **≤54**                 **Reference**                                                                             **Reference**                          
  55--61                  1.074           0.973--1.185                   0.159                                      1.270           1.178--1.369           \<0.001[^\*^](#TN1){ref-type="table-fn"}
  62--69                  1.404           1.276--1.545                   \<0.001[^\*^](#TN1){ref-type="table-fn"}   1.917           1.786--2.056           \<0.001[^\*^](#TN1){ref-type="table-fn"}
  ≥70                     2.922           2.680--3.184                   \<0.001[^\*^](#TN1){ref-type="table-fn"}   4.590           4.316--4.881           \<0.001[^\*^](#TN1){ref-type="table-fn"}
  **RACE**                                                                                                                                                 
  **White**               **Reference**                                                                             **Reference**                          
  Black                   1.867           1.681--2.074                   \<0.001[^\*^](#TN1){ref-type="table-fn"}   1.488           1.380--1.605           \<0.001[^\*^](#TN1){ref-type="table-fn"}
  Other                   0.865           0.770--0.972                   0.014[^\*^](#TN1){ref-type="table-fn"}     0.738           0.680--0.802           \<0.001[^\*^](#TN1){ref-type="table-fn"}
  **YEAR OF DIAGNOSIS**                                                                                                                                    
  **≤2001**               **Reference**                                                                             **Reference**                          
  2002--2006              0.554           0.507--0.605                   \<0.001[^\*^](#TN1){ref-type="table-fn"}   0.765           0.723--0.810           \<0.001[^\*^](#TN1){ref-type="table-fn"}
  ≥2007                   0.420           0.387--0.457                   \<0.001[^\*^](#TN1){ref-type="table-fn"}   0.666           0.629--0.706           \<0.001[^\*^](#TN1){ref-type="table-fn"}
  **HISTOLOGY**                                                                                                                                            
  **G1**                  **Reference**                                                                             **Reference**                          
  G2                      3.247           2.936--3.592                   \<0.001[^\*^](#TN1){ref-type="table-fn"}   1.723           1.634--1.817           \<0.001[^\*^](#TN1){ref-type="table-fn"}
  G3                      10.139          9.195--11.180                  \<0.001[^\*^](#TN1){ref-type="table-fn"}   3.618           3.425--3.822           \<0.001[^\*^](#TN1){ref-type="table-fn"}
  Gx                      14.339          12.410--16.568                 \<0.001[^\*^](#TN1){ref-type="table-fn"}   4.836           4.363--5.361           \<0.001[^\*^](#TN1){ref-type="table-fn"}
  **CLINICAL STAGE**                                                                                                                                       
  **Stage I**             **Reference**                                                                             **Reference**                          
  Stage II                3.118           2.791--3.484                   \<0.001[^\*^](#TN1){ref-type="table-fn"}   1.736           1.621--1.858           \<0.001[^\*^](#TN1){ref-type="table-fn"}
  Stage III               7.342           6.781--7.949                   \<0.001[^\*^](#TN1){ref-type="table-fn"}   2.973           2.820--3.134           \<0.001[^\*^](#TN1){ref-type="table-fn"}
  Stage IV                24.888          22.824--27.140                 \<0.001[^\*^](#TN1){ref-type="table-fn"}   7.869           7.382--8.387           \<0.001[^\*^](#TN1){ref-type="table-fn"}
  **SURGICAL STAGE**                                                                                                                                       
  **Localized**           **Reference**                                                                             **Reference**                          
  Regional                4.736           4.370--5.132                   \<0.001[^\*^](#TN1){ref-type="table-fn"}   2.193           2.086--2.306           \<0.001[^\*^](#TN1){ref-type="table-fn"}
  Distant                 14.836          13.724--16.039                 \<0.001[^\*^](#TN1){ref-type="table-fn"}   4.969           4.711--5.242           \<0.001[^\*^](#TN1){ref-type="table-fn"}
  **RADIATION**                                                                                                                                            
  **NO**                  **Reference**                                                                             **Reference**                          
  YES                     1.537           1.436--1.646                   \<0.001[^\*^](#TN1){ref-type="table-fn"}   1.230           1.174--1.288           \<0.001[^\*^](#TN1){ref-type="table-fn"}
  **CHEMOTHERAPY**                                                                                                                                         
  **NO**                  **Reference**                                                                             **Reference**                          
  YES                     3.753           3.516--4.006                   \<0.001[^\*^](#TN1){ref-type="table-fn"}   1.978           1.833--2.077           \<0.001[^\*^](#TN1){ref-type="table-fn"}
  **TUMOR SIZE**                                                                                                                                           
  **≤28**                 **Reference**                                                                             **Reference**                          
  29--56                  2.424           2.201--2.669                   \<0.001[^\*^](#TN1){ref-type="table-fn"}   1.713           1.625--1.806           \<0.001[^\*^](#TN1){ref-type="table-fn"}
  ≥57                     6.015           5.478--6.605                   \<0.001[^\*^](#TN1){ref-type="table-fn"}   2.713           2.567--2.868           \<0.001[^\*^](#TN1){ref-type="table-fn"}

*HR, Hazard Ratio; CI, Confidence Interval*.

*means p \<0.05, Gx means undifferentiated tissue cells*.

###### 

Multivariate cox regression analysis of cancer-specific survival and Overall survival in the training cohort.

  **Variables**                           **Cancer-specific survival**                                                              **Overall survival**   
  ----------------------- --------------- ------------------------------ ------------------------------------------ --------------- ---------------------- ------------------------------------------
  **AGE**                                                                                                                                                  
  **≤54**                 **Reference**                                                                             **Reference**                          
  55--61                  1.351           1.223--1.493                   \<0.001[^\*^](#TN2){ref-type="table-fn"}   1.437           1.333--1.550           \<0.001[^\*^](#TN2){ref-type="table-fn"}
  62--69                  1.788           1.623--1.971                   \<0.001[^\*^](#TN2){ref-type="table-fn"}   2.186           2.036--2.347           \<0.001[^\*^](#TN2){ref-type="table-fn"}
  ≥70                     3.194           2.922--3.492                   \<0.001[^\*^](#TN2){ref-type="table-fn"}   4.877           4.578--5.195           \<0.001[^\*^](#TN2){ref-type="table-fn"}
  **RACE**                                                                                                                                                 
  **White**               **Reference**                                                                             **Reference**                          
  Black                   1.506           1.354--1.675                   \<0.001[^\*^](#TN2){ref-type="table-fn"}   1.421           1.317--1.534           \<0.001[^\*^](#TN2){ref-type="table-fn"}
  Other                   0.952           0.847--1.070                   0.413                                      0.896           0.825--0.973           0.009[^\*^](#TN2){ref-type="table-fn"}
  **YEAR OF DIAGNOSIS**                                                                                                                                    
  **≤2001**               **Reference**                                                                             **Reference**                          
  2002--2006              0.788           0.721--0.863                   \<0.001[^\*^](#TN2){ref-type="table-fn"}   0.924           0.873--0.978           0.007[^\*^](#TN2){ref-type="table-fn"}
  ≥2007                   0.633           0.580--0.689                   \<0.001[^\*^](#TN2){ref-type="table-fn"}   0.868           0.819--0.9121          \<0.001[^\*^](#TN2){ref-type="table-fn"}
  **HISTOLOGY**                                                                                                                                            
  **G1**                  **Reference**                                                                             **Reference**                          
  G2                      2.007           1.810--2.225                   \<0.001[^\*^](#TN2){ref-type="table-fn"}   1.307           1.238--1.380           \<0.001[^\*^](#TN2){ref-type="table-fn"}
  G3                      3.712           3.338--4.128                   \<0.001[^\*^](#TN2){ref-type="table-fn"}   1.993           1.876--2.117           \<0.001[^\*^](#TN2){ref-type="table-fn"}
  Gx                      4.268           3.663--4.974                   \<0.001[^\*^](#TN2){ref-type="table-fn"}   2.349           2.109--2.616           \<0.001[^\*^](#TN2){ref-type="table-fn"}
  **CLINICAL STAGE**                                                                                                                                       
  **Stage I**             **Reference**                                                                             **Reference**                          
  Stage II                1.591           1.026--2.468                   0.038[^\*^](#TN2){ref-type="table-fn"}     1.382           1.033--1.849           \<0.001[^\*^](#TN2){ref-type="table-fn"}
  Stage III               3.165           2.065--4.850                   \<0.001[^\*^](#TN2){ref-type="table-fn"}   2.212           1.667--2.936           \<0.001[^\*^](#TN2){ref-type="table-fn"}
  Stage IV                7.699           5.029--11.787                  \<0.001[^\*^](#TN2){ref-type="table-fn"}   4.976           3.752--6.599           \<0.001[^\*^](#TN2){ref-type="table-fn"}
  **SURGICAL STAGE**                                                                                                                                       
  **Localized**           **Reference**                                                                             **Reference**                          
  Regional                1.425           0.923--2.200                   0.110                                      1.111           0.833--1.480           0.475
  Distant                 1.668           1.088--2.558                   0.019[^\*^](#TN2){ref-type="table-fn"}     1.229           0.929--1.627           0.149
  **RADIATION**                                                                                                                                            
  **NO**                  **Reference**                                                                             **Reference**                          
  YES                     0.872           0.811--0.937                   \<0.001[^\*^](#TN2){ref-type="table-fn"}   0.799           0.761--0.840           \<0.001[^\*^](#TN2){ref-type="table-fn"}
  **CHEMOTHERAPY**                                                                                                                                         
  **NO**                  **Reference**                                                                             **Reference**                          
  YES                     0.841           0.777--0.911                   \<0.001[^\*^](#TN2){ref-type="table-fn"}   0.866           0.814--0.920           \<0.001[^\*^](#TN2){ref-type="table-fn"}
  **TUMOR SIZE**                                                                                                                                           
  **≤28**                 **Reference**                                                                             **Reference**                          
  29--56                  1.605           1.455--1.771                   \<0.001[^\*^](#TN2){ref-type="table-fn"}   1.368           1.297--1.444           \<0.001[^\*^](#TN2){ref-type="table-fn"}
  ≥57                     2.345           2.118--2.597                   \<0.001[^\*^](#TN2){ref-type="table-fn"}   1.747           1.642--1.858           \<0.001[^\*^](#TN2){ref-type="table-fn"}

*HR, Hazard Ratio; CI, Confidence Interval*.

*means p \<0.05, Gx means undifferentiated tissue cells*.

Comparison With Chemotherapy and Radiotherapy in Each Clinical Stage
--------------------------------------------------------------------

[Figure 4](#F4){ref-type="fig"} shows us the Kaplan-Meier plot in each clinical stage compared with chemotherapy and radiotherapy, the right column shows chemotherapy treatment have made progress in clinical stage II and III, the left column shows radiotherapy treatment have made progress in clinical stage III, both treatment didn\'t show any progress in clinical stage I and IV, the treatment in clinical stage IV even showed worse effect than previous one.

![The Kaplan-Meier plot of each clinical stage compared with chemotherapy and radiotherapy in each phase.](fonc-10-00269-g0004){#F4}

Construction and Validation of the Nomograms for OS and CSS
-----------------------------------------------------------

Some non-significant variables or variables with light effects were excluded. Patient age, histologic grade, clinical stage, tumor size, year of diagnosis, and race were used to construct the nomogram for CSS ([Figure 5](#F5){ref-type="fig"}). Patient age, histologic grade, clinical stage, tumor size, and race were used to construct the nomogram for OS ([Figure 5](#F5){ref-type="fig"}). The exact point for each variable is listed in [Table 4](#T4){ref-type="table"}. We also validated the nomograms internally and externally. The C-index was used to assess the predictive accuracy of the nomograms. For the internal validation of the nomogram, the C-indexes were, respectively, 0.859 (0.847--0.871) and 0.782 (0.772--0.792) for CSS and OS. For the external validation of the nomogram, the C-indexes were, respectively, 0.859 (0.841--0.876) and 0.782 (0.766--0.798) for CSS and OS. The validation for both nomograms showed a good level of agreement on the prediction value ([Figure 6](#F6){ref-type="fig"}).

![Nomograms to predict 3- and 5-year of cancer-specific survival **(A)** and overall survival **(B)** for patients with endometrial carcinoma.](fonc-10-00269-g0005){#F5}

###### 

Scores of prognostic factors in the CSS and OS nomograms.

  **Characteristic**      **OS nomogram**   **CSS nomogram**
  ----------------------- ----------------- ------------------
  **Age**                                   
  ≤ 54                    0                 0
  55--61                  20                12
  62--69                  44                24
  ≥70                     92                49
  **Size**                                  
  ≤ 28                    0                 0
  29--56                  17                19
  ≥57                     32                35
  **Race**                                  
  White                   7                 2
  Black                   26                19
  Other                   0                 0
  **Clinical stage**                        
  Stage I                 0                 0
  Stage II                21                31
  Stage III               48                60
  Stage IV                100               100
  **Tissue grade**                          
  G1                      0                 0
  G2                      14                28
  G3                      38                53
  Gx                      46                58
  **Year of diagnosis**                     
  ≤ 2001                                    0
  2002--2006                                10
  ≥2007                                     20

*Gx means undifferentiated tissue cells*.

![External verification plots of 3-year **(A)** and 5-year **(B)** overall survival nomogram verification curves; 3-year **(C)** and 5-year **(D)** cancer-specific survival nomogram verification curves.](fonc-10-00269-g0006){#F6}

Discussion {#s4}
==========

The survival prognosis of endometrial carcinoma has improved significantly with advances in medical technology; however, there are no studies showing the changes in the survival prognosis of endometrial carcinoma with advancements in medical technology. The X-tile software can provide optimal cut-off points for continuous variables affecting tumor survival prognosis ([@B6]). Using the X-tile software to assess the best cut-off point for the year of diagnosis showed that survival rate of endometrial carcinoma was a turning point in 2001. Because the screening methods for endometrial carcinoma have not changed basically, the improvement in survival rate was probably due to changes in staging ([@B7]); improvement of surgical methods, radiotherapy progress, and chemotherapy progress; comprehensive treatment of endometrial carcinoma ([@B8]); and other factors. There were fewer chemotherapy drugs before 2001, mainly chemotherapeutic drugs such as cisplatin and doxorubicin ([@B9]). These drugs were mainly used for advanced endometrial carcinoma; there are more choices of chemotherapeutic drugs than before ([@B7]) and hormone therapy has been used in the treatment of endometrial carcinoma since 2001 ([@B10]). Through our research, we found that chemotherapy drugs can improve the survival rate of patients in the early stage (clinical stage II and III) ([Figure 4](#F4){ref-type="fig"}), but by extending the observation time, the previous chemotherapy drugs may increase the mortality rate among patients in clinical stage IV. By assessing the patients according to each clinical stage ([Figure 3](#F3){ref-type="fig"}), we found that the survival rate of endometrial carcinoma was improved in patients with three preclinical stages, particularly for patients with clinical stage III, and the improvement in survival rate was the most obvious. In the clinical stage IV, the patient survival rate decreased. Due to the limitation of observation time, it was impossible to completely determine whether the final three curves would coincide. However, in the early stage after the diagnosis of stage IV, there was no advancement in medical technology that could result in a significant increase in survival rate. The optimal time cut-off points for different clinical stages are inconsistent, and the final reason may be due to the inconsistent benefits of medical technology for patients at different stages and at different time periods.

In this study, the X-tile software used the ages of 54, 61, and 69 as the cut-off points, which could better distinguish the survival rate, particularly in terms of OS. Even its role exceeds the effect of histology grade. At the same time, with the tumor diameters of 29 and 56 mm as cut-off values, it can also distinguish its survival rate better than before. Inclusion of these two indicators in our current tumor staging system may improve the current clinical staging system for endometrial carcinoma.

We have constructed a different prognostic model for assessing the CSS and OS of endometrial carcinoma. The CSS predictive model consists of age, clinical stage, pathological tissue grade, tumor size, ethnicity, and diagnostic time, while the OS predictive model consists of the first five items. It can be seen from these differences that different diagnostic times will lead to different survival rates among patients, which indirectly suggests the impact of advancement in medical technology on the survival prognosis of patients with endometrial carcinoma. At the same time, the other difference between the two models is the effect of age at diagnosis on the survival rate. For CSS, the effect of age at diagnosis was no greater than the effect of histopathological grade on survival prognosis; however, for OS, the effect of age at diagnosis was obviously greater than that of the latter. According to the FIGO 2009 staging, the 5-year survival rate of endometrial carcinoma in clinical stage I was about 77.6--89.6%, that of stage III was 73.5%, that of stage III is about 49.4--56.3%, and that of stage IV is about 21.1--22.0%, but the study failed to correct for tumor size and the impact of chemotherapy, and a prediction model was not constructed. Our results are similar with respect to age, histopathological grade, clinical stage, radiotherapy, and other factors on survival rate, although factors such as marriage and radiotherapy were not corrected in our study; however, the effects of these factors were not important. At the same time, our study showed that the effect of tumor size on nomogram was significant, and the chemotherapeutic factors were also corrected in the study. There was a nomogram for predicting the prognosis of endometrial carcinoma in 2010. Age, number of negative lymph nodes, clinical stage, histologic grade, and histologic type were used to construct this nomogram, and this model showed that the OS rate of patients with endometrial carcinoma was greater, and the effect was greater. The histologic type had the smallest effect, but due to the small number of patients, only the 3-year survival rate is calculated, the model was not stable, and the predicted performance C-index of the 3-year OS was only 0.746 ± 0.011 ([@B11]). An analysis of endometrial carcinoma in the SEER database from 1973 to 1987 has been performed previously. A total of 41,120 patients were enrolled according to the FIGO 1971 staging standard. The 5-year survival rates for clinical stages I, II, III, and IV were 86--93.9, 72.9, 48.1, and 25.4%, respectively. All of those are similar to the previous study results, but failed to correct for the effects of radiotherapy, chemotherapy, and tumor size, and failed to construct a model ([@B12]). Previous studies that used biomarkers to construct endometrial carcinoma models have included fewer patients, the prognostic factors included were not sufficient ([@B4]), and the use of biomarkers worsened the economic benefits. Other factors related to the survival rate for endometrial carcinoma patients are LVSI (lymph-vascular space invasion) and some co-morbidity, as for the LVSI, there are some controversies about it, a study showed us that LVSI does not significantly compromise the survival outcome of Chinese EEC patients ([@B13]). But in some studies, LVSI shows potential prognostic value about locoregional recurrences in EEC patients ([@B14]).

In this study, to make the model more refined, we removed factors such as metastasis, surgical stage, radiotherapy, and chemotherapy. Radiotherapy and chemotherapy are meaningful factors, but did not yield an obvious effect on the model. We excluded these factors to make the model more concise for clinical application. The C-index identified in this study could be stabilized at around 0.8, which means our nomograms have a higher accuracy for predicting survival than before.

The strength of this study is that the number of patients included was large, and the overall observation time was longer. We also assessed more influencing factors, used correct analytical methods, drew meaningful conclusions, and constructed a model with practical application value. The limitation of our study was the failure to include more of the possibly related factors into the model because of limitations of database, censor data and the ease of use, such as marital status, Lymph node status, LVSI, and the chemical biomarkers. As most of the patients were white, failure to include more non-whites may have some impact on the application of the model. There may have some selection bias because nearly half of patients wasn\'t included in our study. Meanwhile, we didn\'t develop a very accurate model for the convenient use in our clinical practice, for example, the detailed chemotherapy and radiotherapy protocol. At the same time, the data of our build model and calibration model are from the SEER database, which may have some impact on its application. In the future, it is necessary to use other databases for correction.

In conclusion, this study found that advancement in medical technology may only yield survival benefit among patients with stages I--III endometrial carcinoma, but not among those with clinical stage IV disease. This study used routine clinical data to construct a nomogram model of 3- and 5-year CSS and OS among patients with endometrial carcinoma. This model provides a good prognostication tool for the clinical practice of gynecologists and general practitioners.
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